Norditropin (somatropin (rDNA origin) for injection)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.


Approval Status:

Approved February 1997

Specific Treatments:

Growth failure in children

Find Related Trials for The Following Conditions

General Information

Norditropin is indicated for the long-term treatment of children who have growth failure due to inadequate secretion of endogenous (pituitary gland produced) growth hormone.

Additional Information

Human growth hormone is responsible for stimulating normal skeletal, connective tissue, muscle and organ growth in children and adolescents. It is also active in normal protein, carbohydrate and fat metabolism. If the amount of growth hormone production by the body is insufficient, short stature, reduced muscle and soft tissue mass and altered nutrient metabolism result. Such problems significantly impact an individual’s physical function throughout life, if not treated appropriately.